《大行報告》瑞銀削中國中免(01880.HK)目標價至153元 評級「買入」
瑞銀發表報告,料內地打擊代購帶來的影響,將持續至下半年,或對中國中免(01880.HK)的收入及盈利帶來進一步的壓力,惟基於現時價格差距,料代購最快或於第四季末回歸。
該行預料,中國中免下半年經營會持續改善,料海南銷售勢頭持續改善,受惠經濟復甦帶來人均消費額反彈;另內地航企恢復國際航班或有助收入增長,惟復甦料呈漸進,意味不會出現即時轉勢。
瑞銀稱中國中免H股過去三個月股價累計回落逾25%,認為短期逆風已反映於股價,維持「買入」評級。瑞銀對其今年至2025年各年盈測分別下調28%、25%及24%,並將其H股目標價由238元削至153元,以反映今年盈利增長料呆滯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.